[{"orgOrder":0,"company":"Optimi Health","sponsor":"SABI Mind","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ SABI Mind","highestDevelopmentStatusID":"1","companyTruncated":"Optimi Health \/ SABI Mind"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Bloom Psychedelic Therapy and Research Centre","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ Bloom Psychedelic Therapy and Research Centre","highestDevelopmentStatusID":"6","companyTruncated":"Optimi Health \/ Bloom Psychedelic Therapy and Research Centre"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Optimi Health \/ Not Applicable"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Optimi Health \/ Not Applicable"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Optimi Health \/ Not Applicable"},{"orgOrder":0,"company":"Optimi Health","sponsor":"M\u0101tai Medical Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ M\u0101tai Medical Research Institute","highestDevelopmentStatusID":"5","companyTruncated":"Optimi Health \/ M\u0101tai Medical Research Institute"}]

Find Clinical Drug Pipeline Developments & Deals by Optimi Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the terms of the agreement, Optimi will provide Mātai with a quantity of its validated GMP Full Spectrum Natural Psilocybin extract for the treatment of methamphetamine use disorder.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 09, 2024

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Sponsor : Mātai Medical Research Institute

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : MDMA-AT (3,4-methylenedioxymethamphetamine) mainly acts as a releaser of serotonin (5-HT) and noradrenaline, and to a lesser extent also of dopamine, which is investigated for the treatment of Posttraumatic Stress Disorder.

                          Brand Name : MDMA-AT

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 14, 2023

                          Lead Product(s) : Midomafetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety eff...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 07, 2023

                          Lead Product(s) : Psilocybine,Midomafetamine

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Research shows that up to 80 percent of patients with advanced cancer for Psilocybin are likely to suffer distressing thoughts around death and up to 50 percent of patients with generally incurable conditions are likely to have psychiatric diagnoses.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 10, 2022

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Optimi will supply Bloom with sufficient biomass of natural psilocybin to begin conducting its previously announced trial in partnership with the IMPACT Clinical Trial Accelerator Program housed within Alberta’s Life Sciences Innovation Hub at the Univ...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 13, 2022

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Bloom Psychedelic Therapy and Research Centre

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The Company has signed an agreement which will provide SABI Mind’s trained clinical staff with supplies of GMP psilocybin and 3,4-Methylenedioxymethamphetamine (“MDMA”), pending the anticipated approval of its previously announced licensing amendme...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 28, 2022

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : SABI Mind

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank